{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Dynavax Technologies Corporation"},"Symbol":{"label":"Symbol","value":"DVAX"},"Address":{"label":"Address","value":"2100 POWELL STREET,SUITE 900, EMERYVILLE, California, 94608, United States"},"Phone":{"label":"Phone","value":"+1 510 848-5100"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product."},"CompanyUrl":{"label":"Company Url","value":"https://www.dynavax.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David F. Novack","title":"President & Chief Operating Officer"},{"name":"Ouzama Henry","title":"Vice President-Clinical Development"},{"name":"Patricia Novy","title":"Vice President-Medical Affairs"},{"name":"Robert Janssen","title":"Chief Medical Officer & SVP-Clinical Development"},{"name":"Ryan Spencer","title":"Chief Executive Officer & Director"},{"name":"Todd Lopeman","title":"Vice President-Technical Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}